Implementation of a next-generation sequencing-based targeted approach for full-length CYP3A4 gene sequencing.
Agnija KivraneViktorija IgumnovaJanis KimsisLauma FreimaneDarja SadovskaAnda ViksnaIlva PoleRenāte RankaPublished in: Pharmacogenomics (2021)
Aim: To evaluate the application of next-generation sequencing-based targeted protocol for full-length CYP3A4 gene sequencing analysis. Materials & methods: The developed sequencing protocol was applied to analyze human DNA samples (n = 7) obtained from tuberculosis patients admitted to the Riga East University Hospital, Center of Tuberculosis and Lung diseases. Results: The sequencing data quality was sufficient for the detection of already known genetic variants, as well as for identifying rare and novel variants dispersed throughout the CYP3A4 gene with a high degree of confidence. Conclusion: Developed protocol can be applied in subpopulation level association studies to determine whether specific genetic variants or variant combinations from multiple regions of the CYP3A4 gene are of clinical significance.
Keyphrases
- copy number
- genome wide
- single cell
- randomized controlled trial
- circulating tumor
- genome wide identification
- mycobacterium tuberculosis
- healthcare
- endothelial cells
- primary care
- dna methylation
- cancer therapy
- hiv aids
- quality improvement
- emergency department
- drug delivery
- cell free
- adverse drug
- antiretroviral therapy
- case control